• In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program.

• At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed's broader sleep-health and digital platform story may be.

• Next, we'll examine how the ventilator sales suspension and softer fiscal 2027 outlook affect ResMed's existing investment narrative and expectations.

The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

ResMed Investment Narrative Recap

To stay invested in ResMed today, you need to believe its core sleep apnea and digital health platform can offset near term turbulence in ventilators and costs. The FDA Class 1 recall and suspended Astral ventilator sales focus attention on product quality and regulatory risk, which now sit alongside pricing and reimbursement as the key near term overhang. The main near term catalyst is how quickly management can reassure the market that the broader sleep business can absorb this US$75 million revenue headwind.

The most relevant recent announcement here is ResMed's softer fiscal 2027 outlook, which explicitly factors in the ventilator sales suspension and cost inflation. That update sits in sharp contrast to the otherwise solid FY26 result, with higher sales and earnings, and a 10% lift in the quarterly US$0.66 dividend, and it effectively reframes expectations around the timing and strength of any margin or earnings recovery catalyst.

Yet behind the dividend increase and buyback completion, investors should be aware that ResMed's Class 1 recall and suspended ventilator sales could...

Read the full narrative on ResMed (it's free!)

ResMed's narrative projects $6.5 billion revenue and $1.8 billion earnings by 2029.

Uncover how ResMed's forecasts yield a $247.93 fair value , a 10% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were previously assuming revenue of about US$6.8 billion and earnings near US$1.8 billion by 2029, but after this recall and ventilator pause you can see how opinions on cost inflation risk and long term growth could end up much further apart.

Explore 6 other fair value estimates on ResMed - why the stock might be worth just $224.10!